Senior Computational Biologist - Early Discovery Oncology

The role

You will integrate massive datasets to nominate targets, validate disease biology, and define precision oncology strategies. You will partner with biologists, chemists, and data scientists to develop and scale methods for target discovery and validation.

What you will do

• Evaluate molecular evidence for target nomination and validation
• Pilot novel methods for target discovery, validation, and early patient population hypotheses
• Define internal criteria for target data packages and early patient population strategy
• Connect innovative analysis methods to platform and engineering teams
• Partner with biologists, medicinal chemists, translational, and portfolio leads
• Present data analysis to decision makers and stakeholders

Required qualifications

• PhD in a relevant field (computational biology, bioinformatics, systems biology, cancer biology, etc.) with a very strong computational focus and 3+ years of experience in biotech or pharma industry O
• Domain expertise in precision oncology and target id
• Strong understanding of patient genetics and druggability of disease relevant pathways
• Experience applying computational methods (including probabilistic, statistical, and/or machine learning techniques) to analyze and integrate complex biological and/or human clinical data in a high le
• Exceptional data visualization skills
• Excellent cross-functional communication skills

Nice to have

• Experience building a target discovery engine using public and proprietary datasets
• Experience designing high-throughput screens with CRISPR or small molecule perturbations to validate therapeutic hypotheses
• Previous exposure to efficient drug program advancement from proof of concept to IND

Benefits

• Annual bonus
• Equity compensation
• Comprehensive benefits package

About the company

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. The company uses the Recursion OS, an AI-native, end-to-end drug discovery and development platform.